Data from: Flortaucipir PET uncovers relationships between tau and β-amyloid in aging, primary age related tauopathy, and Alzheimer disease
Data files
Jul 10, 2024 version files 308.09 KB
-
figure1.csv
5.12 KB
-
figure2.csv
9.11 KB
-
figure3_labels.csv
10.92 KB
-
figure3.csv
6.07 KB
-
figure4.csv
10.82 KB
-
figureS1.csv
14.72 KB
-
figureS2_S4.csv
9.11 KB
-
figureS3.csv
13.79 KB
-
figureS5.csv
127.92 KB
-
figureS6.csv
80.35 KB
-
figureS7.csv
5.74 KB
-
figureS8.csv
7.65 KB
-
README.md
6.77 KB
Abstract
[18F]-Flortaucipir PET is considered a good biomarker of Alzheimer’s disease. However, it is unknown how flortaucipir is associated with the distribution of tau across brain regions and how these associations are influenced by β-amyloid. It is also unclear whether flortaucipir can detect tau in definite primary age-related tauopathy (PART). We identified 248 individuals at Mayo Clinic that had undergone [18F]-flortaucipir PET during life, had died, and undergone an autopsy, 239 cases of which also had β-amyloid PET. We assessed nonlinear relationships between flortaucipir uptake in nine medial temporal and cortical regions, Braak tau stage and Thal β-amyloid phase using generalized additive models. We found that flortaucipir uptake was greater with increasing tau stage in all regions. Increased uptake at low tau stages in medial temporal regions was only observed in cases with high β-amyloid phase. Flortaucipir uptake linearly increased with β-amyloid phase in medial temporal and cortical regions. The highest flortaucipir uptake occurred with high Alzheimer’s disease neuropathologic change (ADNC) scores, followed by low-intermediate ADNC scores, then PART, with entorhinal cortex providing the best differentiation between groups. Flortaucipir PET had limited ability to detect PART and imaging defined PART did not correspond with pathologically defined PART. In summary, spatial patterns of flortaucipir mirrored histopathological tau distribution, were influenced by β-amyloid phase, and were useful for distinguishing different ADNC scores and PART.
Each of these file corresponds to a figure in the main paper or in the supplementary materials.
figure1.csv
Thal
is Thal phase which is measured by histopathology. This is an
ordinal variable with no units.Braak
is Braak neurofibrillary tangle stage. This is an ordinal
variable with no units. Braak stages are sometimes styled using Roman
numerals.Group
is a composite variable representing how we combined Thal
phase and Braak stage.
figure2.csv
region
is the location in the brain where the flortaucipir PET
tracer was measured. The regions are as follows:- ERC, entorhinal cortex
- Anterior HP or AHP, anterior hippocampus
- Fusiform or FFG, fusiform gyrus
- Inferior temporal or ITG, inferior temporal gyrus
- Superior frontal or SFG, superior frontal gyrus
- Precuneus or PRCU, precuneus
- Superior parietal or SPG, superior parietal gyrus
- Calcarine or CAL, calcarine
- Precentral or PrCG, precentral gyrus
thal
is the Thal phase as infigure1.csv
.braak
is the Braak stage as infigure1.csv
.estimates
corresponds to the model-based estimated geometric mean
standardized uptake value ratio (SUVR) from the generalized additive
model. This variable is a ratio and unitless although some
researchers use the phrase “SUVR units.”
figure3.csv
and figure3_labels.csv1
This figure can be thought of as a 6 Thal phases (rows) by 7 Braak
stages (columns) grid and within each “cell” is a 3x3 sub array
corresponding to the 9 regions. The estimates for the figure are in a
(6 * 3) x (7 * 3) = 18 x 21 matrix found in figure3.csv
. They are scaled
to the unit interval.
The file figure3_labels.csv
gives the coordinates for the region
labels.
position_x_axis
is the position on the x-axis in terms of the unit
interval.position_y_axis
is the position on the y-axis in terms of the unit
interval.roi
is the region of interest, or simply region, label. The
regions here are abbreviated. See above for the mapping between
abbreviation and region of interest.
figure4.csv
erc_tau
is the entorhinal cortex flortaucipir SUVR value for each
individual in the study and is plotted in panel B.group
is the four-level composite group used throughout the paper.braak
is the Braak stage as infigure1.csv
.thal
is the Thal phase as infigure1.csv
.cerad
stands for “Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD)” and is an ordinal neuropathology
variable.pib
is the Pittsburgh Compound B (PiB) group. PiB is the amyloid
PET ligand used in this study. The label “PiB +” corresponds to an
elevated (abnormal) PiB SUVR, “PiB -“ corresponds to a normal PiB
SUVR, and “No PiB” means the participant did not have a PiB scan.
figureS1.csv
region
is the 9-level region or region of interest (ROI) as in
figure2.csv
.position_x_axis
is the position on the x-axis for plotting.contrast
is an ordinal variable which indicates which Braak stages
are being contrasted (or differenced).estimates
is the estimate for the contrast, or the estimated
percentage difference based on the generalized additive models
summarized in Figure 2.lcl
corresponds to the lower 95% confidence limit.ucl
corresponds to the upper 95% confidence limit.
figureS2_S4.csv
The data for Figure S2 and S4 are the same and can be thought of as a
variation of Figure 2 but using partial volume correction (PVC) to
account for atrophy. Figure S2 has Braak stage on the x-axis and lines
for Thal phase while Figure S4 has Thal phase on the x-axis with lines
for Braak stage.
region
is the 9-level region or region of interest (ROI) as in
figure2.csv
.thal
is the Thal phase as infigure1.csv
.braak
is the Braak stage as infigure1.csv
.estimates
corresponds to the model-based estimated geometric mean
standardized uptake value ratio (SUVR) from the generalized additive
model fit to PVC data.
figureS3.csv
This figure is similar to Figure S1 but here Thal phases are being
contrast.
region
is the 9-level region or region of interest (ROI) as in
figure2.csv
.position_x_axis
is the position on the x-axis for plotting.contrast
is an ordinal variable which indicates which Thal phases
are being contrasted (or differenced).estimates
is the estimate for the contrast, or the estimated
percentage difference in means based on the
generalized additive models summarized in Figure 2.lcl
corresponds to the lower 95% confidence limit.ucl
corresponds to the upper 95% confidence limit.
figureS5.csv
This figure gives the estimated mean SUVR for combinations
of Braak stage and Thal phase for six different model fits.
model
is the model being fit. This is a categorical variable with
six levels.region
is the 9-level region or region of interest (ROI) as in
figure2.csv
.position_y_axis
is the y-axis position for plotting. It
corresponds to the Thal phase with jittering.braak
is the Braak stage as infigure1.csv
.estimates
is the estimated geometric mean flortaucipir SUVR for the
Braak-Thal combination for a particular model.lcl
corresponds to the lower 95% confidence limit.ucl
corresponds to the upper 95% confidence limit.
figureS6.csv
region
is the 9-level region or region of interest (ROI) as in
figure2.csv
.group
is an eight-level grouping variable indicating the person-level
group.taupet
is the within-region, person-level flortaucipir PET SUVR value.
figureS7.csv
position_x_axis
gives the position on the x-axis (the Braak axis)
for the point plotted.position_y_axis
gives the position on the y-axis (the Thal axis)
for the point plotted.erc_group
is the entorhinal cortex (ERC) SUVR group.number_subjects
is the number of participants for the given
combination of Thal, Braak, CERAD, and PiB. (For CERAD and PiB, see
figure4.csv
.)cerad
as infigure4.csv
.pib
as infigure4.csv
.
figureS8.csv
thal
is the Thal phase as infigure1.csv
.centiloid
is the amyloid PET centiloid value. This is a rescaling
of PiB whereby 0 represents the mean SUVR value for a reference group
of controls and 100 represents the mean SUVR value for a reference
group of individuals with Alzheimer’s. Note that values below 0 and
above 100 are possible.cerad
as infigure4.csv
.group
is the four-level composite group used throughout the paper.
These data are from 248 participants recruited from Mayo Clinic, Rochester, MN, who had flortaucipir PET imaging during life, had died, and had undergone an autopsy evaluation. All patients were enrolled into one of three NIH funded cohort studies including the Mayo Clinic Alzheimer’s Disease Research Center (PI: Petersen), The Mayo Clinic Study of Aging (PI: Petersen) and the Neurodegenerative Research Group (PIs: Josephs/Whitwell).